Moderna Begins Phase 1 Trial for mRNA Ebola Vaccine

Moderna (NASDAQ: MRNA) announced Tuesday it has initiated a Phase 1 clinical trial for its experimental mRNA vaccine targeting the Bundibugyo ebolavirus, dosing the first participants in Canada. The move marks a key step in developing a defense against a strain of the virus for which there is currently no approved vaccine.

Trial Details and Partnership

The early-stage study, cleared by Health Canada, aims to enroll approximately 80 healthy adults across three sites. According to the company, the trial will assess the safety of the vaccine candidate, designated mRNA-1469, and its ability to generate an immune response. The vaccine utilizes the same messenger RNA technology foundational to Moderna's successful COVID-19 shot.

The trial is part of an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has pledged up to $50 million to support early testing and manufacturing. Moderna stated that if the vaccine is eventually approved, its agreement with CEPI includes making at least 500,000 doses available at access pricing to low- and middle-income countries.

Ad

Addressing a Public Health Emergency

The Bundibugyo strain is driving the world's second-largest Ebola outbreak on record in the Democratic Republic of Congo. The U.S. Centers for Disease Control and Prevention reported 3,748 confirmed cases and 1,657 confirmed deaths from the outbreak as of August 1. Both the World Health Organization and the Africa CDC have declared the situation a public health emergency.

For investors, this trial highlights Moderna's ongoing efforts to leverage its mRNA platform to address a pipeline of infectious diseases beyond COVID-19. The progress in developing a vaccine for a recognized global health threat could further validate the technology's broad applicability.